Aurinia Pharmaceuticals Inc. has initiated PRESERVE, a Phase 4 study evaluating Lupkynis, or voclosporin, in combination with belimumab, obinutuzumab or anifrolumab for adults with active lupus nephritis. The multicentre study plans to enrol approximately 150 patients across about 50 sites in the United States, with the proportion achieving complete renal response after six months serving as the primary endpoint.
The study represents more than routine post-marketing evidence generation. It tests whether combining a calcineurin inhibitor with a biologic, mycophenolic acid analogue and corticosteroid can produce faster and deeper kidney responses than those generally achieved with currently available multidrug regimens. However, PRESERVE is an open-label, single-group study rather than a randomised controlled trial, creating important limits around how confidently any improvement can be attributed to voclosporin, the selected biologic or the overall treatment combination.
Why does PRESERVE matter as lupus nephritis care shifts toward earlier combination therapy?
Lupus nephritis treatment is moving away from a simple sequence in which clinicians begin with conventional immunosuppression, wait for an inadequate response and add another medicine months later. Updated treatment frameworks increasingly support earlier use of combination regimens because persistent proteinuria and continuing kidney inflammation can translate into irreversible nephron loss even when serum creatinine initially appears stable.
Current combination strategies commonly pair corticosteroids and a mycophenolic acid analogue with either a calcineurin inhibitor such as voclosporin or a biologic such as belimumab. PRESERVE goes further by bringing both approaches together. Participants will receive voclosporin alongside belimumab, obinutuzumab or anifrolumab, while also taking mycophenolate mofetil or mycophenolic acid and oral prednisone or an equivalent corticosteroid.
This creates a four-component regimen aimed at several parts of the disease process simultaneously. The potential advantage is that kidney inflammation, autoantibody-producing immune pathways and podocyte injury could be addressed before prolonged proteinuria causes additional structural damage. The corresponding risk is that greater pharmacological intensity may add infection risk, treatment burden and monitoring complexity without delivering a sufficiently large improvement over established triple therapy.
PRESERVE therefore reflects a central unresolved question in lupus nephritis management. The field increasingly accepts that one immune pathway may not be enough, but it has not yet established how many therapies should be combined, which mechanisms should be paired or which patients are most likely to justify the added risk and cost.
How could combining voclosporin with biologics target kidney damage more rapidly?
Voclosporin and the three biologics included in PRESERVE do not perform identical functions. Voclosporin inhibits calcineurin-dependent T-cell activation and can reduce proteinuria partly through stabilisation of podocytes, the specialised cells that help maintain the kidney’s filtration barrier. Its Phase 3 development programme showed that adding voclosporin to mycophenolate mofetil and reduced-dose corticosteroids increased complete renal response compared with background therapy alone.
Belimumab inhibits B-cell activating factor, reducing survival signals that contribute to abnormal B-cell activity and autoantibody production. Its lupus nephritis evidence developed over a longer treatment period and demonstrated improved kidney response and a lower risk of renal events when added to standard therapy. Pairing belimumab with voclosporin could therefore combine relatively rapid proteinuria reduction with slower modulation of the autoreactive B-cell environment.
Obinutuzumab offers a more direct B-cell depletion strategy through targeting CD20. Phase 3 evidence showed higher complete renal response when obinutuzumab was added to standard therapy, supporting its subsequent entry into the lupus nephritis treatment landscape. Combining obinutuzumab with voclosporin may provide intensive suppression of B-cell-driven disease while simultaneously addressing T-cell signalling and the filtration barrier.
Anifrolumab blocks signalling through the type I interferon receptor, targeting a pathway strongly associated with systemic lupus erythematosus. Its position in PRESERVE is more exploratory because it is established for moderate to severe systemic lupus erythematosus rather than severe active lupus nephritis. Earlier lupus nephritis research produced biological and numerical efficacy signals, but the Phase 2 programme did not meet its primary endpoint.
The study consequently brings together three combinations with different levels of supporting evidence. The belimumab and obinutuzumab regimens build on drugs already established in active lupus nephritis, while the anifrolumab regimen examines whether interferon blockade can become more effective when paired with voclosporin and background immunosuppression.
What can the open-label single-group design establish, and what will remain uncertain?
PRESERVE is designed as a practical evidence-generation study rather than a confirmatory efficacy trial. All participants enter a single experimental group and receive voclosporin with one of the permitted biologics. There is no placebo group, no background-therapy-only group and no randomised comparison between belimumab, obinutuzumab and anifrolumab.
This design can produce useful information about feasibility, treatment persistence, early renal responses and adverse events when the therapies are combined. It may also identify whether response patterns appear consistent across biologic mechanisms or whether one combination generates a particularly strong or weak signal.
The absence of a concurrent control group will nevertheless make interpretation difficult. Improvements in proteinuria may result from voclosporin, the biologic, mycophenolic acid therapy, corticosteroids, natural variation in disease activity or the combined effect of all four components. Comparisons with historical clinical trials will be complicated by differences in eligibility criteria, steroid tapering, baseline proteinuria, biopsy class, endpoint definitions and prior treatment exposure.
Treatment timing introduces another source of heterogeneity. Patients receiving belimumab or anifrolumab may already be using the biologic or may initiate it by the beginning of the study. Participants assigned to the obinutuzumab regimen must have received at least two administrations before screening. The amount of biologic exposure before voclosporin is introduced may therefore vary considerably.
The planned enrolment of approximately 150 participants is substantial for a post-marketing lupus nephritis study, but the usefulness of individual regimen comparisons will depend on how patients are distributed across the three biologics. Small or uneven subgroups could produce unstable response estimates and make apparent differences difficult to separate from patient-selection effects.
Why is complete renal response at six months clinically important but not sufficient?
The decision to measure complete renal response after six months places speed at the centre of PRESERVE. Earlier reduction in proteinuria is clinically meaningful because continuing protein leakage indicates ongoing disruption of the kidney filtration barrier and is associated with poorer long-term renal outcomes.
Voclosporin has already demonstrated an ability to accelerate proteinuria reduction when added to mycophenolate mofetil and corticosteroids. PRESERVE will examine whether pairing it with a biologic can push a larger proportion of patients toward complete renal response within a relatively short treatment window.
Six months is also commercially and clinically relevant because physicians need early indicators of whether a demanding regimen is working. A combination that does not produce meaningful improvement within that period may be difficult to justify when it requires multiple immunosuppressive agents, laboratory monitoring and biologic administration.
Complete renal response remains a composite clinical endpoint rather than direct proof that chronic kidney damage has been prevented. Its interpretation depends on the protocol’s requirements for proteinuria, kidney function, corticosteroid exposure, rescue treatment and treatment adherence. A patient may experience substantial improvement without meeting every component, while another may meet the endpoint without eliminating residual histological inflammation.
Longer follow-up will therefore be essential. The most important unanswered questions include whether early responses remain durable, whether kidney function is preserved, whether corticosteroid exposure can be reduced and whether the regimen lowers the risk of flares or renal-related events. A six-month response signal would support the therapeutic concept, but it would not settle the long-term benefit-risk calculation.
How do the three biologic combinations differ in regulatory and clinical maturity?
The belimumab combination has a comparatively straightforward clinical rationale. Belimumab has established lupus nephritis efficacy and is incorporated into contemporary combination-treatment strategies. The principal question is not whether belimumab has kidney activity, but whether adding voclosporin produces enough incremental benefit to justify simultaneous use.
Obinutuzumab also enters PRESERVE with positive controlled lupus nephritis evidence and a mechanism capable of producing deeper B-cell depletion. Its combination could be particularly relevant where rapid control and sustained suppression of B-cell activity are desired. However, more intensive depletion may raise concerns about infection, immunoglobulin levels and the ability to manage repeated treatment safely.
Anifrolumab creates the greatest scientific uncertainty. Type I interferon signalling is biologically important in lupus, and previous studies have generated encouraging renal signals. Yet the pathway has not been validated in lupus nephritis to the same regulatory standard as belimumab, obinutuzumab or voclosporin.
A favourable anifrolumab cohort could stimulate further controlled development of combined interferon and calcineurin inhibition. An unfavourable or ambiguous result would be difficult to interpret because the study lacks a comparator and includes several concomitant therapies. PRESERVE may therefore be better suited to deciding whether anifrolumab combinations merit additional trials than to establishing a new treatment standard.
Could safety and treatment burden become the main barriers to multitarget therapy?
The biological appeal of targeting several non-overlapping pathways does not remove the risks created by overlapping immunosuppression. Participants may be exposed to voclosporin, a biologic, mycophenolic acid therapy and corticosteroids at the same time, producing a treatment profile that requires close coordination between nephrology and rheumatology teams.
Infection will be one of the most closely watched risks. B-cell-directed therapies can impair humoral immune function, while mycophenolic acid analogues and corticosteroids further suppress immune responses. Anifrolumab has its own infection-related considerations, including viral infections, while obinutuzumab introduces infusion-related and prolonged B-cell-depletion concerns.
Voclosporin requires monitoring of kidney function, blood pressure and potential drug interactions. Calcineurin inhibitors can produce haemodynamic changes in estimated glomerular filtration rate, creating a challenge when investigators must distinguish expected pharmacological effects from worsening lupus nephritis or cumulative kidney injury.
Treatment burden could also affect adherence. Oral medicines, corticosteroid tapering, laboratory surveillance and intravenous or subcutaneous biologic administration must be maintained together. Even a clinically effective regimen may struggle to achieve broad adoption if patients and treatment centres find it difficult to administer consistently.
PRESERVE will be most valuable if it reports safety by biologic subgroup, captures treatment discontinuations and explains how adverse events affect dosing. A pooled safety result across three mechanistically different biologics could obscure clinically important differences.
Could PRESERVE expand Lupkynis use or mainly support selected high-risk patients?
For Aurinia Pharmaceuticals Inc., PRESERVE is a strategic effort to position Lupkynis within an increasingly crowded lupus nephritis market. The treatment landscape now includes several approved mechanisms, making the key commercial question less about whether voclosporin works and more about where it belongs within multidrug treatment pathways.
Combination evidence could protect Lupkynis from being viewed as an alternative to biologics. Instead, voclosporin could be positioned as a complementary oral therapy that helps accelerate kidney response while biologics address broader immune drivers. That positioning would be especially valuable as clinicians adopt earlier combination treatment.
Broad use would still require evidence that the additional response exceeds the added cost, safety risk and operational burden. Payers may question simultaneous use of multiple branded therapies unless the regimen demonstrates a clearly differentiated outcome, such as faster complete renal response, fewer renal events or reduced corticosteroid exposure.
PRESERVE’s eligibility criteria may also constrain generalisation. Participants must have biopsy-confirmed proliferative lupus nephritis, an estimated glomerular filtration rate of at least 45 millilitres per minute per 1.73 square metres and urine protein-to-creatinine ratios below 5 grams per gram. Results may not directly apply to patients with more advanced kidney dysfunction, extreme proteinuria or different biopsy patterns.
The most realistic near-term outcome may therefore be evidence supporting selected patients who remain active despite background treatment, require faster proteinuria control or have clinical features suggesting that multiple immune pathways should be targeted. Wider adoption would probably require controlled comparative evidence.
What should clinicians and industry observers watch as PRESERVE progresses?
Recruitment will provide the first indication of whether specialised treatment centres consider these combinations practical enough for routine investigation. Enrolling approximately 150 eligible adults across the United States may be challenging because lupus nephritis is heterogeneous, biopsy requirements are restrictive and competing trials are seeking similar patient populations.
The distribution of participants among belimumab, obinutuzumab and anifrolumab will be equally important. Balanced enrolment would permit more informative exploratory comparisons, while concentration in one regimen could limit conclusions about the broader multitarget strategy.
Investigators will need to show more than a headline complete renal response rate. The pace of proteinuria reduction, stability of estimated glomerular filtration rate, corticosteroid use, treatment discontinuations, serious infections and differences between biologic subgroups will determine whether the findings change practice.
PRESERVE is unlikely to provide definitive proof that one combination is superior because its design does not support that conclusion. Its real contribution could be identifying which mechanistic pairings are sufficiently active, tolerable and operationally feasible to justify larger randomised studies.
The study therefore marks an important transition for lupus nephritis drug development. The field is no longer asking only whether individual therapies can improve response when added to conventional treatment. It is beginning to ask how approved therapies can be combined intelligently, how early they should be used and whether deeper immune intervention can preserve more kidney function without creating an unacceptable safety burden.
